Massido

Nebivolol, the active ingredient in Massido, is a beta blocker presented as a tablet for oral use. It treats hypertension in adult patients. GNH USA supplies Massido as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is indicated for the management of high blood pressure, acting on the cardiovascular system to lower systemic pressure.

Hypertension: reduces systolic and diastolic blood pressure in patients with essential hypertension.

Nebivolol may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain in the head. - Dizziness: sensation of light‑headedness, especially on standing. - Fatigue: feeling unusually tired or weak. - Nausea: upset stomach or urge to vomit. - Bradycardia: slower than normal heart rate. - Peripheral edema: swelling of the ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Symptomatic hypotension: dangerously low blood pressure causing faintness. - Acute heart failure exacerbation: worsening of cardiac function. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Liver injury: abnormal liver function tests or jaundice. - Bronchospasm: narrowing of airways, especially in patients with asthma.

Nebivolol requires careful monitoring and specific safety measures before and during therapy. - Blood pressure monitoring: check regularly to ensure therapeutic targets are met. - Hepatic impairment: use cautiously in patients with severe liver disease. - Abrupt discontinuation: taper dose to avoid rebound hypertension. - Respiratory conditions: avoid in uncontrolled asthma or severe COPD. - Drug interactions: review concomitant medications for potential additive effects. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Nebivolol can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Other β‑blockers: may cause excessive bradycardia or hypotension. - Calcium‑channel blockers (verapamil, diltiazem): increase nebivolol plasma levels. - CYP2D6 inhibitors (paroxetine, fluoxetine): raise nebivolol concentrations. - Insulin or sulfonylureas: mask hypoglycaemic symptoms. - Antihypertensive combinations: risk of additive blood‑pressure lowering.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce antihypertensive effect. - Diuretics: monitor electrolytes and renal function. - Antidepressants (sertraline): observe for heart‑rate changes. - Antidiabetic agents: watch for altered glucose control. - Lipid‑lowering drugs (statins): assess for rare muscle toxicity.